|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Cash and cash equivalents held at Consolidated Funds | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Corporate treasury investments | ||||||||||||||||||||
| Investments, including accrued performance allocations of $6,608.2 and $7,620.3 as of June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Investments of Consolidated Funds | ||||||||||||||||||||
| Due from affiliates and other receivables, net | ||||||||||||||||||||
| Due from affiliates and other receivables of Consolidated Funds, net | ||||||||||||||||||||
| Fixed assets, net | ||||||||||||||||||||
| Lease right-of-use assets, net | ||||||||||||||||||||
| Deposits and other | ||||||||||||||||||||
| Intangible assets, net | ||||||||||||||||||||
| Deferred tax assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and equity | ||||||||||||||||||||
| Debt obligations | ||||||||||||||||||||
| Loans payable of Consolidated Funds | ||||||||||||||||||||
| Accounts payable, accrued expenses and other liabilities | ||||||||||||||||||||
| Accrued compensation and benefits | ||||||||||||||||||||
| Due to affiliates | ||||||||||||||||||||
| Deferred revenue | ||||||||||||||||||||
| Deferred tax liabilities | ||||||||||||||||||||
| Other liabilities of Consolidated Funds | ||||||||||||||||||||
| Lease liabilities | ||||||||||||||||||||
| Accrued giveback obligations | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Common stock, $0.01 par value, 100,000,000,000 shares authorized (353,389,038 and 357,374,023 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively) | ||||||||||||||||||||
| Additional paid-in-capital | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Non-controlling interests in consolidated entities | ||||||||||||||||||||
| Total equity | ||||||||||||||||||||
| Total liabilities and equity |
Loading...
